How Handl Was 'Built To Buy' By UCB
The Inside Story On Gene Therapy Acquisition
Executive Summary
UCB has been looking to go deep into the gene therapy space for some time, CSO Dhaval Patel tells Scrip, saying that instead of treating symptoms, "you should be going for a cure."
You may also be interested in...
SynOx Seeks Solution For TGCT With Roche Antibody
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Novartis Puts Down $50m For Mesoblast COVID-19 Cell Therapy
The Australian company's off-the-shelf cell therapy fell foul of the US FDA for graft-versus-host disease recently but Novartis is backing remestemcel-L as a potential treatment for acute respiratory distress syndrome.
GSK Venture Capital Arm Goes Independent With $500m Fund
Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.
Need a specific report? 1000+ reports available
Buy Reports